Healthcare Industry Updates Patient Derived Xenograft Models Market

Patient Derived Xenograft/PDx Models Market Worth 167.6 Million
USD by 2022
The key factors driving the growth of this market include the growing demand for personalized
medicine, continuous support for cancer research from the public as well as private sectors, and growth
in the number of R&D activities in the pharmaceutical industry. The growing use of humanized PDX
models is posing a lucrative opportunity in this market.
According to a new market research report "Patient Derived Xenograft Models Market by Type (Mouse
& Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug
Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022",
published by MarketsandMarkets™.
The market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017,
at a CAGR of 16.7%.
Don’t miss the opportunities in global Patient Derived Xenograft Models Market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
The various players in the PDx Models Market include Crown Bioscience Inc. (US), WuXi AppTec (China),
Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River
Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd.
(China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs
(US).
Browse and in-depth TOC on "Patient Derived Xenograft Models Market"
44 – Tables
34 – Figures
148 – Pages
By tumor type, the gastrointestinal tumor models segment accounted for the largest share of the
market in 2017
On the basis of tumor type, the PDx Models Market has been segmented into gastrointestinal tumor
models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological
tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017,
the gastrointestinal tumors segment is expected to account for the largest share of the global PDx
Models Market. The respiratory tumors segment, on the other hand, is expected to be the fastest-
growing segment during the forecast period. Growth in this segment is mainly driven by the increasing
focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in
lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.
By application, the preclinical drug development and basic cancer research held the largest market
share in 2017